Shares of Theravance Biopharma Inc. (NASDAQ:TBPH) have earned a consensus recommendation of “Hold” from the eight brokerages that are currently covering the stock. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $36.00.

TBPH has been the subject of several recent research reports. Guggenheim reiterated a “positive” rating and set a $40.00 target price on shares of Theravance Biopharma in a research report on Monday, September 19th. Zacks Investment Research upgraded shares of Theravance Biopharma from a “hold” rating to a “buy” rating and set a $41.00 target price for the company in a research report on Tuesday, October 4th. Robert W. Baird cut shares of Theravance Biopharma from a “neutral” rating to an “underperform” rating and upped their target price for the company from $19.00 to $24.00 in a research report on Wednesday, October 12th. Leerink Swann reiterated an “outperform” rating and set a $33.00 target price (down previously from $35.00) on shares of Theravance Biopharma in a research report on Monday, October 31st. Finally, Evercore ISI initiated coverage on shares of Theravance Biopharma in a research report on Monday, August 29th. They set a “buy” rating and a $41.00 target price for the company.

Shares of Theravance Biopharma (NASDAQ:TBPH) opened at 34.11 on Monday. Theravance Biopharma has a one year low of $12.87 and a one year high of $38.92. The stock’s market capitalization is $1.63 billion. The company’s 50 day moving average price is $31.98 and its 200 day moving average price is $26.41.

In related news, SVP Brett K. Haumann sold 9,509 shares of the company’s stock in a transaction on Friday, August 19th. The shares were sold at an average price of $27.97, for a total value of $265,966.73. Following the completion of the transaction, the senior vice president now directly owns 197,391 shares of the company’s stock, valued at approximately $5,521,026.27. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Bradford J. Shafer sold 49,122 shares of the company’s stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $27.46, for a total transaction of $1,348,890.12. Following the completion of the transaction, the executive vice president now directly owns 241,686 shares of the company’s stock, valued at $6,636,697.56. The disclosure for this sale can be found here. 4.70% of the stock is currently owned by insiders.

A number of institutional investors have recently made changes to their positions in the company. Bellevue Group AG bought a new position in shares of Theravance Biopharma during the first quarter worth $215,000. First Manhattan Co. raised its position in shares of Theravance Biopharma by 0.6% in the second quarter. First Manhattan Co. now owns 1,021,233 shares of the biopharmaceutical company’s stock worth $23,171,000 after buying an additional 5,692 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of Theravance Biopharma by 25.4% in the second quarter. Bank of New York Mellon Corp now owns 179,769 shares of the biopharmaceutical company’s stock worth $4,079,000 after buying an additional 36,397 shares during the last quarter. California State Teachers Retirement System raised its position in shares of Theravance Biopharma by 25.7% in the second quarter. California State Teachers Retirement System now owns 76,061 shares of the biopharmaceutical company’s stock worth $1,726,000 after buying an additional 15,542 shares during the last quarter. Finally, Swiss National Bank raised its position in shares of Theravance Biopharma by 19.8% in the second quarter. Swiss National Bank now owns 53,942 shares of the biopharmaceutical company’s stock worth $1,224,000 after buying an additional 8,900 shares during the last quarter. 70.02% of the stock is owned by hedge funds and other institutional investors.

About Theravance Biopharma

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

5 Day Chart for NASDAQ:TBPH

Receive News & Stock Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related stocks with our FREE daily email newsletter.